**FOI Ref: 6288**

**Category(ies): Clinical - Drugs**

**Subject: Immunoglobulin Treatments**

**Date Received: 14/03/2022**

|  |  |
| --- | --- |
| **Your request:** | **Our response:** |
| I have a Freedom of Information request which I hope you’ll be able to help me with (questions are set out below) |
| 1. In the past 6 months (latest 6 months available) how many patients have received the following Immunoglobulin treatments (for any disease):
* Cutaquig
* Cuvitru
* Gammanorm
* Hizentra
* Hyqvia
* Subgam
* Privigen
* Octagam
* Intratect
* Gamunex
* Kiovig
* Panzyga
* Iqymune
* Gammaplex
 | Intratect 8 patientsPrivigen <5 patients |
| 1. In the past 6 months (latest 6 months available) how many patients have received the following treatments (for any disease):
* Berinert (Human C1-esterase inhibitor)
* Cinryze (Human C1-esterase inhibitor)
* Firazyr (Icatibant injection)
* Orladeyo (Berotralstat)
* Ruconest (Recombinant Human C1-esterase inhibitor)
* Takhzyro (Lanadelumab)
 | Neither The Rotherham NHS Foundation Trust Pharmacy or Blood Bank issue the products mentioned. |
| 1. In the past 2 years, how many patients have been diagnosed (primary and secondary) with Hereditary Angioedema (ICD-10 code D84.1)
 | <5 patients (time period Jan 2020 – Dec 2021) |
| 1. For the patients identified in Q3 above, how many patients have been treated (for any condition) in the past 6 months with the following drugs:
* Danazol
* Oxandralone
* Stanozolol
 | < 5 patients currently on danazol, (supplied by the GP) and none on the other drugs mentioned. |
| **Less than 5 (in figures) <5**The Trust considers that information you have requested would in some instances where very low volumes exist, clearly identify an individual and constitutes sensitive personal information. It is therefore exempt under section 40 (2) of the Freedom of Information Act and will not be released as this will likely contravene the 1st (used fairly, lawfully and transparently) and 6th (handled in a way that ensures appropriate security, including protection against unlawful or unauthorised processing, access, loss destruction or damage) data protection principles. Also, Data Protection Act Principle 1 state that when processing sensitive personal information, at least one of the conditions in Schedule 3 is met. The section 40 exemption is an absolute exemption and as such no public interest test should be applied. |